Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study

Keyphrases

• Obsessive-compulsive 100%
• Amantadine 100%
• Selective Serotonin Reuptake Inhibitors 100%
• Augmentation Therapy 100%
• Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) 83%
• Obsessive-compulsive Disorder 50%
• OC Symptoms 50%
• Anxiety Level 33%
• Depression Level 33%
• N-methyl-D-aspartic Acid Receptor 33%
• Pharmacotherapy 16%
• Competitive Antagonist 16%
• Glutamate 16%
• Glutamatergic 16%
• Inhibitor Treatment 16%
• Adjunctive Therapy 16%
• Placebo-controlled Study 16%
• Scale Levels 16%
• Statistical Manual of Mental Disorders 16%
• Fourth Edition 16%
• Compulsion 16%
• Adjunction 16%
• Text Revision 16%
• Glutamatergic Dysfunction 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Selective Serotonin Reuptake Inhibitor 100%
• Amantadine 100%
• Symptom 50%
• Obsessive Compulsive Disorder 50%
• Aspartic Acid 33%
• Receptor 33%
• Pharmacotherapy 16%
• Glutamic Acid 16%
• Placebo-Controlled Study 16%
• Obsession 16%
• DSM-IV-TR 16%

Neuroscience

• Amantadine 100%
• Selective Serotonin Reuptake Inhibitor 100%
• Obsessive-Compulsive Disorder 50%
• N-Methyl-D-Aspartic Acid 33%
• Eicosanoid Receptor 33%
• Placebo 16%
• Glutamic Acid 16%
• Adjuvant Therapy 16%
• Compulsive Behavior 16%
• Obsession 16%
• Diagnostic and Statistical Manual of Mental Disorders 16%